Abstract 1410P
Background
Around 15% of patients (pts) with NSCLC harbor the KRAS G12C mutation. In a changing landscape of KRAS G12C treatment (tx), there is a need for updated real-world evidence on characteristics and outcomes of routine clinical practice. Here we present characteristics, tx patterns, outcomes, and direct healthcare costs in pts with NSCLC and KRAS G12C in the Spanish clinical practice.
Methods
Observational, retrospective, multicenter study in pts with newly diagnosed locally advanced (not candidate for radical tx) or metastatic NSCLC and KRAS G12C. Pts participating in clinical trials with RAS inhibitors were excluded. The study collected clinical and economic data from medical records and administrative databases from 1st Jan 2016 to 9th Mar 2022 (diagnosis period: Jan 2016-Oct 2021).
Results
A total of 127 pts were included (median age 65 years, 71% male, 43%/54% current/former smokers, 82% ECOG≤2, 57% ≥2 metastatic site). PD-L1 expression was analysed in 104 pts at baseline: 19/104 (18%) pts had a PD-L1 expression <1%, 45/104 (43%) pts 1-50%, and 40/104 (39%) pts ≥50%. 94 pts (74%) received systemic tx. The most common first line tx was platinum-based chemotherapy alone (71%). Table shows progression free survival and overall survival. 124 and 103 pts had available global and disease-related (d-r) economic data, respectively. Total global cost over study period was €5,780,686 (total global mean cost per pt: €46,618) with a total pharmacological cost of €2,373,384 (mean cost per pt: €19,140). Total d-r cost was €4,245,504 (total d-r mean cost per pt: €41,218) with a d-r pharmacological cost of €2,177,712 (mean cost per pt: €21,142). Table: 1410P
PFS, median (95%CI), m | OS, median (95%CI), m | |
TL 1 | ||
CTx (n=60) | 2.8 (2.4-4.0) | 5.0 (3.3-7.4) |
IO (n=23) | 17.8 (3.7-NR) | 31.9 (7.4-NR) |
CTx + IO (n=10) | 13.2 (0.2-NR) | NR (0.5-NR) |
TL 2 | ||
CTx (n=9) | 1.6 (1.0-9.0) | 9.2 (1.5-14.3) |
IO (n=20) | 4.2 (1.4-12.5) | 10.4 (2.8-17.9) |
TL 3 | ||
CTx (n=7) | 2.1 (0.1-9.9) | 6.6 (0.1-25.8) |
Date of diagnosis * | ||
Jan 2016-Sep 2017 (n=24)‡ | NA | 6.8 (4.4-18.5) |
Oct 2017-Oct 2021 (n=66)§ | NA | 7.7 (4.0-20.5) |
CI, confidence interval; CTx, chemotherapy; FU, follow up; IO, immunotherapy; m, months; NA, not applicable; NR, not reached; OS, overall survival; PFS, progression free survival; TL, treatment line *Periods due to a major change in Spain: IO can be used as TL 1 from Oct 2017 ‡Median FU6.8 m §Median FU6.6 m
Conclusions
The real-world data confirm limited outcomes for most KRASG12C pts and emphasize the high clinical and economic burden of these pts’ care in an evolving tx landscape. Evaluating the impact of new and effective targeted therapies is warranted.
Clinical trial identification
Editorial acknowledgement
Medical writing support provided by Irene Mansilla from TFS HealthScience and funded by Amgen S.A.
Legal entity responsible for the study
Amgen S.A.
Funding
Amgen S.A.
Disclosure
N. Reguart Aransay: Financial Interests, Personal, Advisory Board: Roche, MSD, Takeda, Bayer, Novartis, Sanofi, Janssen, AstraZeneca, Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Boehringer, Guardant, BMS, Pfizer, Amgen, Novartis. O.J. Juan Vidal: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck Sharp & Dohme, Lilly, Takeda, AstraZeneca, Janssen; Financial Interests, Personal, Invited Speaker: Roche/Genentech; Financial Interests, Institutional, Funding: AstraZeneca. E. Arriola: Financial Interests, Personal, Advisory Board: Roche, Boehringer Ingelheim, Lilly; Financial Interests, Personal, Invited Speaker: Takeda, MSD, AstraZeneca, BMS, Thermo Fisher Scientific, Guardant Health, Pfizer; Financial Interests, Personal, Other, Co-founder: Trialing Health; Financial Interests, Institutional, Research Grant: AstraZeneca. S. Palanca: Financial Interests, Personal, Speaker, Consultant, Advisor: Roche Pharma, AstraZeneca, Lilly; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Research Funding: Roche Pharma, AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer, Amgen, Takeda; Financial Interests, Personal, Research Grant: Roche Pharma, Amgen. L. Planellas, A. Lloansi Vila: Financial Interests, Personal, Full or part-time Employment: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20